Faculty: Bruce G. Pollock, MD, PhD, FRCP(C)
Professor, Departments of Psychiatry and Pharmacology
General Research Area: Geriatric Psychopharmacology
NOT TAKING NEW GRADUATE STUDENTS
Dr. Bruce Pollock teaches and conducts research in geriatric clinical psychopharmacology with over 300 peer reviewed publications and is listed by ISI as among the 1% most cited authors in the field of geriatric psychiatry.
Dr. Pollock received his PhD in Pharmacology from the University of Pittsburgh. His work includes: 1) clinical studies examining neurochemical selectivity, pharmacokinetics, and neurophysiological-therapeutic effects of conventional or newly derived/modified agents for the treatment of depression and the behavioral disturbances of dementia, and 2) examination of age-related changes in drug metabolism and pharmacodynamics toward optimizing treatment with antidepressants and antipsychotics. He has had a leadership role in numerous clinical trials and the U.S. National Institutes of Health has continuously funded his research since 1990.
Dr. Pollock is a Distinguished Fellow of the American Psychiatric Association (APA), a Fellow of the Canadian Psychiatric Association, and has been honored with the Distinguished Investigator Award of the American Association for Geriatric Psychiatry. He has also been awarded the Jack Weinberg Memorial Award for excellence in Geriatric Psychiatry from the APA, the Award for Research in Geriatric Psychiatry by the American College of Psychiatrists, and is the recipient of the 2014 William B. Abrams Award in Geriatric Clinical Pharmacology from the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
Li CH, Pollock BG, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR, for the DIADS-2 Research Group: Population pharmacokinetic modeling of sertraline treatment in Alzheimer’s Disease patients: The DIADS-2 study. J Clin Pharmacol: 53:234-9, 2013.
Chow TW, Fam D, Graff-Guerrero A, Verhoeff NPG, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG: Fluodeoxyglucose positron emission tomography (FDG-PET) in semantic dementia after 6 months of memantine: An open-label pilot study. Int J Geriatr Psychiat: 28:319-25, 2013.
Gerretsen P, Pollock BG: Cognitive risks of anticholinergics in the elderly. Aging Health: 9:159-166, 2013.
Ismail Z, Chetachi A, Emeremni C, Houck PR, Mazumdar S, Rosen J, Rajji TR, Pollock BG, Mulsant BH: A comparison of the E-BEHAVE-AD, NBRS and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. Am J Geriatr Psychiat: 21:78-87, 2013.
Lenze EJ, Lotrich FE, Nowotny P, Pollock BG, Dixon D, Dore PM, Hinrichs AL, Butters MA: Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. Int J Neuropsychopharmacol: 16:279-88, 2013.
Voineskos, A, Foussias G, Lerch, J, Felsky, D, Remington, G, Rajji, T, Lobaugh, N, Pollock BG, Mulsant, B: Neuroimaging Evidence for the Deficit Subtype of Schizophrenia. JAMA Psychiat: 70:472-80, 2013.
Day GS, Farb NAS, Tang-Wai DF, Masellis M, Black SE, Freedman M, Pollock BG, Chow TW: Salience Network Resting-State Activity: Prediction of Frontotemporal Dementia Progression.JAMA. Neurology: 70:1249-1253, 2013.
Nebes RD, Pollock BG, Perera S, Halligan EM, Saxton JA: The greater sensitivity of elderly APOE є4 carriers to anticholinergic medications is independent of cerebrovascular disease risk. Am J Geriat Pharmacother: 10: 185-192, 2012.
Sherer EA, Sale M, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR: Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic building. J Pharmacokinet Pharmacodyn: 39:393-414, 2012.
Wessels AM, Jin Y, Pollock BG, Lange AC, Vrijens B, Fagiolini A, Kupfer D, Rucci P, Kepple G, Anderton J, Buttenfield J, Bies RR, Frank E: Adherence to Escitalopram Treatment in Depression: A study of electronically compiled dosing histories in the “Depression, The Search for Phenotypes” study. Int Clin Psychopharmacol: 27:291-7, 2012.
Wojtalik JA, Eack SM, Pollock BG, Keshavan MS: Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia. Psychiat Res: 204:61-7, 2012.
Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR: Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 51: 1587-1591, 2011.
Bigos KL, Bies RR, Pollock BG, Lowy JJ, Zhang F, Weinberger DR: Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiat. 16: 620-625, 2011